Milica Pesic

About Milica Pesic

Milica Pesic, With an exceptional h-index of 30 and a recent h-index of 24 (since 2020), a distinguished researcher at Univerzitet u Beogradu, specializes in the field of cancer research.

His recent articles reflect a diverse array of research interests and contributions to the field:

Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts

69P Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts

High-throughput screening of multidrug-resistance markers in non-small cell lung carcinoma patient-derived cells–contribution to personalized treatment

Sinteza i citotoksičnost novih derivata sklareola

Evading multidrug resistance in glioblastoma with natural compound sclareol and its novel derivatives

34P Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy

Novel artesunate–pyrimidine-based hybrids with anticancer potential against multidrug-resistant cancer cells

Novel hybrids of sclareol and 1, 2, 4-triazolo [1, 5-a] pyrimidine show collateral sensitivity in multidrug-resistant glioblastoma cells

Milica Pesic Information

University

Position

Institute for Biological Research "Sinisa Stankovic" - National Institute of Republic of Serbia

Citations(all)

2543

Citations(since 2020)

1711

Cited By

1472

hIndex(all)

30

hIndex(since 2020)

24

i10Index(all)

70

i10Index(since 2020)

58

Email

University Profile Page

Google Scholar

Milica Pesic Skills & Research Interests

cancer research

Top articles of Milica Pesic

Title

Journal

Author(s)

Publication Date

Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts

Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT); 2023 Mar 6-8; Paris, France

Sofija Jovanović Stojanov

Ana Podolski-Renić

Jelena Dinić

Miodrag Dragoj

Mirna Jovanović

...

2023

69P Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts

ESMO Open

S Jovanović Stojanov

A Podolski-Renic

J Dinić

M Dragoj

M Jovanović

...

2023/3/1

High-throughput screening of multidrug-resistance markers in non-small cell lung carcinoma patient-derived cells–contribution to personalized treatment

ONCOLOGY INSIGHTS

Sofija Jovanović Stojanov

Ana Podolski-Renić

Jelena Dinić

Miodrag Dragoj

Mirna Jovanović

...

2023/10

Sinteza i citotoksičnost novih derivata sklareola

Book of Abstracts and Proceedings: 59th meeting of the Serbian Chemical Society; 2023 Jun 1-2; Novi Sad, Serbia

Pavle A Stojković

Ana Stepanović

Ema Lupšić

Nataša Terzić Jovanović

Miroslav Novaković

...

2023

Evading multidrug resistance in glioblastoma with natural compound sclareol and its novel derivatives

Book of abstracts: 8th Congress of Serbian neuroscience society with international participation; 2023 May 31-Jun 2; Belgrade, Serbia

Ema Lupšić

Ana Stepanović

Pavle Stojković

Nataša Terzić-Jpvanović

Miroslav Novaković

...

2023

34P Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy

ESMO Open

J Dinić

A Podolski-Renic

M Dragoj

S Jovanović Stojanov

A Stepanović

...

2023/10/1

Novel artesunate–pyrimidine-based hybrids with anticancer potential against multidrug-resistant cancer cells

New Journal of Chemistry

Ljiljana Koračak

Ema Lupšić

Nataša Terzić Jovanović

Mirna Jovanović

Miroslav Novakovic

...

2023

Novel hybrids of sclareol and 1, 2, 4-triazolo [1, 5-a] pyrimidine show collateral sensitivity in multidrug-resistant glioblastoma cells

Bioorganic Chemistry

Pavle Stojković

Ana Kostić

Ema Lupšić

Nataša Terzić Jovanović

Miroslav Novaković

...

2023/9/1

New anti-glioblastoma strategy with natural compounds sclareol and doxorubicin

Book of abstracts-8th Congress of Serbian neuroscience society with international participation; 2023 May 31-Jun 2; Belgrade, Serbia

Ana Stepanović

Ema Lupšić

Jelena Dinić

Ana Podolski-Renić

Milica Pajović

...

2023

Coleon U, Isolated from Plectranthus mutabilis Codd., Decreases P-Glycoprotein Activity Due to Mitochondrial Inhibition

Pharmaceutics

Sofija Jovanović Stojanov

Epole N Ntungwe

Jelena Dinić

Ana Podolski-Renić

Milica Pajović

...

2023/7/12

Novel functional immunoassay for identification of multidrug resistance markers in non-small cell lung carcinoma patient-derived cells

EACR 2023 Congress: Innovative Cancer Science; 2023 Jun 12-15; Torino, Italy

Ana Stepanović

Jelena Dinić

Ana Podolski-Renić

Sofija Jovanović Stojanov

Miodrag Dragoj

...

2023

Biotinylated selenocyanates: Potent and selective cytostatic agents

Bioorganic Chemistry

Jesús M Roldán-Peña

Adrián Puerta

Jelena Dinić

Sofija Jovanović Stojanov

Aday González-Bakker

...

2023/4/1

Autophagy inhibition sensitises glioblastoma cells to Src family kinase inhibitors Si306 and its prodrug

Congress abstracts: Annual Congress of the European Association for Cancer Research EACR 2022: Innovative Cancer Service: Translating Biology to Medicine; 2022 Jun 20-23; Seville, Spain

Sofija Jovanović Stojanov

Ana Stepanović

Mila Ljujić

Ema Lupšić

Ana Podolski-Renić

...

2022

Ispitivanje matriksnih metaloproteinaza i fokalne adhezione kinaze kao farmakoloških meta kod nesitnoćelijskog karcinoma pluća

Knjiga sažetaka: Treći Kongres biologa Srbije: Osnovna i primenjena istraživanja: Metodika nastave; 2022 Sep 21-25; Zlatibor, Serbia

Sofija Jovanović Stojanov

Ana Podolski-Renić

Mirna Jovanović

Milica Pešić

Tijana Stanković

...

2022

Cytotoxic Activity of diterpenes from Plectranthus spp. for MDR cancer therapy

Abstract Book: STRATAGEM’s 5th Annual Meeting: New Diagnostic and Therapeutic Tools against Multidrug Resistant Tumours; 2022 Jun 29-Jul 1; Coimbra, Portugal

Vera Isca

Gabrielle Bangay

Salvatore Princiotto

Jelena Dinić

Milica Pešić

...

2022

Decreased TSPAN14 Expression Contributes to NSCLC Progression

Life

Mirna Jovanović

Tijana Stanković

Sonja Stojković Burić

Jasna Banković

Jelena Dinić

...

2022/8/23

Inhibicija autofagije senzitizuje ćelije glioblastoma na inhibitore Src tirozin-kinaze, derivate pirazolo [3, 4-d] pirimidina Si306 i pro-Si306

Treći kongres biologa Srbije

Sofija Jovanović Stojanov

Ana Kostić

Mila Ljujić

Ema Lupšić

Miodrag Dragoj

...

2022

Neuro-Oncology Advances

Masafumi Miyai

Tomohiro Kanayama

Fuminori Hyodo

Takamasa Kinoshita

Takuma Ishihara

...

2020

Influence of PARP inhibition on 5-hmC level in NSCLC

Spetses summer school: Cancer epigenetics: Principles, Applications and Single-cell resolution; 2022 Aug 28-Sep 3; Spteses Island, Greece

Ana Sarić

Jovana Rajić

Marija Đorđević

Mirna Jovanović

Ana Podolski-Renić

...

2022

A 3D Biomimetic System for Testing Anticancer Drug Sensitivity

Miodrag Dragoj

Jasmina Stojkovska

Sofija Jovanović Stojanov

Bojana Obradović

Milica Pešić

2022/7/23

See List of Professors in Milica Pesic University(Univerzitet u Beogradu)

Co-Authors

academic-engine